Reviews Rapamune


No reviews yet.

Rapamune Drug Description
RAPAMUNE
(sirolimus) Oral Solution and Tablets

BOX WARNING: IMMUNOSUPPRESSION, USE IS NOT RECOMMENDED IN LIVER OR LUNG
TRANSPLANT PATIENTS

Increased susceptibility to infection and the possible development of
lymphoma and other malignancies may result from immunosuppression

Increased susceptibility to infection and the possible development of lymphoma
may result from immunosuppression. Only physicians experienced in immunosuppressive
therapy and management of renal transplant patients should use Rapamune®.
Patients receiving the drug should be managed in facilities equipped and staffed
with adequate laboratory and supportive medical resources. The physician responsible
for maintenance therapy should have complete information requisite for the follow-up
of the patient [see WARNINGS AND PRECAUTIONS]

The safety and efficacy of Rapamune (sirolimus) as immunosuppressive
therapy have not been established in liver or lung transplant patients, and
therefore, such use is not recommended [see WARNINGS AND PRECAUTIONS].
Liver Transplantation - Excess Mortality, Graft Loss, and Hepatic Artery
Thrombosis (HAT)

The use of Rapamune in combination with tacrolimus was associated with excess
mortality and graft loss in a study in de novo liver transplant patients.
Many of these patients had evidence of infection at or near the time of death.
In this and another study in de novo liver transplant patients, the
use of Rapamune in combination with cyclosporine or tacrolimus was associated
with an increase in HAT; most cases of HAT occurred within 30 days post-transplantation
and most led to graft loss or death [see WARNINGS AND PRECAUTIONS].

Lung Transplantation - Bronchial Anastomotic Dehiscence

Cases of bronchial anastomotic dehiscence, most fatal, have been reported
in de novo lung transplant patients when Rapamune has been used as part
of an immunosuppressive regimen [see WARNINGS AND PRECAUTIONS].

DRUG DESCRIPTION



What are the possible side effects of sirolimus (Rapamune)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

fast heart rate;
pain when you breathe, feeling short of breath;
chest pain, feeling weak or tired;
coughing up blood or mucus;
feeling like you might pass out;
pale skin, easy bruising or bleeding,...
Read All Potential Side Effects for Rapamune »




Rapamune (sirolimus) is an immunosuppressive agent. Sirolimus is a macrocyclic
lactone produced by Streptomyces hygroscopicus. The chemical name of
sirolimus (also known as rapamycin) is (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,
34a-hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]
oxaazacyclohentriacontine-1,5,11,28,29 (4H,6H,31H)-pentone.
Its molecular formula is C51H79NO13 and its
molecular weight is 914.2. The structural formula of sirolimus is illustrated
as follows.








Sirolimus is a white to off-white powder and is insoluble in water, but freely soluble in benzyl alcohol, chloroform, acetone, and acetonitrile.
Rapamune is available for administration as an oral solution containing 1 mg/mL
sirolimus. Rapamune is also available as a tan, triangular-shaped tablet containing
0.5 mg sirolimus, as a white, triangular-shaped tablet containing 1 mg sirolimus,
and as a yellow-to-beige triangular-shaped tablet containing 2 mg sirolimus.
The inactive ingredients in Rapamune Oral Solution are Phosal 50 PG® (phosphatidylcholine, propylene glycol, mono- and di-glycerides, ethanol, soy fatty acids, and ascorbyl palmitate) and polysorbate 80. Rapamune Oral Solution contains 1.5% - 2.5% ethanol.
The inactive ingredients in Rapamune Tablets include sucrose, lactose, polyethylene
glycol 8000, calcium sulfate, microcrystalline cellulose, pharmaceutical glaze,
talc, titanium dioxide, magnesium stearate, povidone, poloxamer 188, polyethylene
glycol 20,000, glyceryl monooleate, carnauba wax, dl-alpha tocopherol,
and other ingredients. The 0.5 mg and 2 mg dosage strengths also contain yellow
iron (ferric) oxide and brown iron (ferric) oxide.
Last reviewed on RxList: 5/17/2010




Rapamune Drug Description
RAPAMUNE
(sirolimus) Oral Solution and Tablets

BOX WARNING: IMMUNOSUPPRESSION, USE IS NOT RECOMMENDED IN LIVER OR LUNG
TRANSPLANT PATIENTS

Increased susceptibility to infection and the possible development of
lymphoma and other malignancies may result from immunosuppression

Increased susceptibility to infection and the possible development of lymphoma
may result from immunosuppression. Only physicians experienced in immunosuppressive
therapy and management of renal transplant patients should use Rapamune®.
Patients receiving the drug should be managed in facilities equipped and staffed
with adequate laboratory and supportive medical resources. The physician responsible
for maintenance therapy should have complete information requisite for the follow-up
of the patient [see WARNINGS AND PRECAUTIONS]

The safety and efficacy of Rapamune (sirolimus) as immunosuppressive
therapy have not been established in liver or lung transplant patients, and
therefore, such use is not recommended [see WARNINGS AND PRECAUTIONS].
Liver Transplantation - Excess Mortality, Graft Loss, and Hepatic Artery
Thrombosis (HAT)

The use of Rapamune in combination with tacrolimus was associated with excess
mortality and graft loss in a study in de novo liver transplant patients.
Many of these patients had evidence of infection at or near the time of death.
In this and another study in de novo liver transplant patients, the
use of Rapamune in combination with cyclosporine or tacrolimus was associated
with an increase in HAT; most cases of HAT occurred within 30 days post-transplantation
and most led to graft loss or death [see WARNINGS AND PRECAUTIONS].

Lung Transplantation - Bronchial Anastomotic Dehiscence

Cases of bronchial anastomotic dehiscence, most fatal, have been reported
in de novo lung transplant patients when Rapamune has been used as part
of an immunosuppressive regimen [see WARNINGS AND PRECAUTIONS].

DRUG DESCRIPTION



What are the possible side effects of sirolimus (Rapamune)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

fast heart rate;
pain when you breathe, feeling short of breath;
chest pain, feeling weak or tired;
coughing up blood or mucus;
feeling like you might pass out;
pale skin, easy bruising or bleeding,...
Read All Potential Side Effects for Rapamune »




Rapamune (sirolimus) is an immunosuppressive agent. Sirolimus is a macrocyclic
lactone produced by Streptomyces hygroscopicus. The chemical name of
sirolimus (also known as rapamycin) is (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,
34a-hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]
oxaazacyclohentriacontine-1,5,11,28,29 (4H,6H,31H)-pentone.
Its molecular formula is C51H79NO13 and its
molecular weight is 914.2. The structural formula of sirolimus is illustrated
as follows.








Sirolimus is a white to off-white powder and is insoluble in water, but freely soluble in benzyl alcohol, chloroform, acetone, and acetonitrile.
Rapamune is available for administration as an oral solution containing 1 mg/mL
sirolimus. Rapamune is also available as a tan, triangular-shaped tablet containing
0.5 mg sirolimus, as a white, triangular-shaped tablet containing 1 mg sirolimus,
and as a yellow-to-beige triangular-shaped tablet containing 2 mg sirolimus.
The inactive ingredients in Rapamune Oral Solution are Phosal 50 PG® (phosphatidylcholine, propylene glycol, mono- and di-glycerides, ethanol, soy fatty acids, and ascorbyl palmitate) and polysorbate 80. Rapamune Oral Solution contains 1.5% - 2.5% ethanol.
The inactive ingredients in Rapamune Tablets include sucrose, lactose, polyethylene
glycol 8000, calcium sulfate, microcrystalline cellulose, pharmaceutical glaze,
talc, titanium dioxide, magnesium stearate, povidone, poloxamer 188, polyethylene
glycol 20,000, glyceryl monooleate, carnauba wax, dl-alpha tocopherol,
and other ingredients. The 0.5 mg and 2 mg dosage strengths also contain yellow
iron (ferric) oxide and brown iron (ferric) oxide.
Last reviewed on RxList: 5/17/2010




Rapamune Drug Description
RAPAMUNE
(sirolimus) Oral Solution and Tablets

BOX WARNING: IMMUNOSUPPRESSION, USE IS NOT RECOMMENDED IN LIVER OR LUNG
TRANSPLANT PATIENTS

Increased susceptibility to infection and the possible development of
lymphoma and other malignancies may result from immunosuppression

Increased susceptibility to infection and the possible development of lymphoma
may result from immunosuppression. Only physicians experienced in immunosuppressive
therapy and management of renal transplant patients should use Rapamune®.
Patients receiving the drug should be managed in facilities equipped and staffed
with adequate laboratory and supportive medical resources. The physician responsible
for maintenance therapy should have complete information requisite for the follow-up
of the patient [see WARNINGS AND PRECAUTIONS]

The safety and efficacy of Rapamune (sirolimus) as immunosuppressive
therapy have not been established in liver or lung transplant patients, and
therefore, such use is not recommended [see WARNINGS AND PRECAUTIONS].
Liver Transplantation - Excess Mortality, Graft Loss, and Hepatic Artery
Thrombosis (HAT)

The use of Rapamune in combination with tacrolimus was associated with excess
mortality and graft loss in a study in de novo liver transplant patients.
Many of these patients had evidence of infection at or near the time of death.
In this and another study in de novo liver transplant patients, the
use of Rapamune in combination with cyclosporine or tacrolimus was associated
with an increase in HAT; most cases of HAT occurred within 30 days post-transplantation
and most led to graft loss or death [see WARNINGS AND PRECAUTIONS].

Lung Transplantation - Bronchial Anastomotic Dehiscence

Cases of bronchial anastomotic dehiscence, most fatal, have been reported
in de novo lung transplant patients when Rapamune has been used as part
of an immunosuppressive regimen [see WARNINGS AND PRECAUTIONS].

DRUG DESCRIPTION



What are the possible side effects of sirolimus (Rapamune)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

fast heart rate;
pain when you breathe, feeling short of breath;
chest pain, feeling weak or tired;
coughing up blood or mucus;
feeling like you might pass out;
pale skin, easy bruising or bleeding,...
Read All Potential Side Effects for Rapamune »




Rapamune (sirolimus) is an immunosuppressive agent. Sirolimus is a macrocyclic
lactone produced by Streptomyces hygroscopicus. The chemical name of
sirolimus (also known as rapamycin) is (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,
34a-hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]
oxaazacyclohentriacontine-1,5,11,28,29 (4H,6H,31H)-pentone.
Its molecular formula is C51H79NO13 and its
molecular weight is 914.2. The structural formula of sirolimus is illustrated
as follows.








Sirolimus is a white to off-white powder and is insoluble in water, but freely soluble in benzyl alcohol, chloroform, acetone, and acetonitrile.
Rapamune is available for administration as an oral solution containing 1 mg/mL
sirolimus. Rapamune is also available as a tan, triangular-shaped tablet containing
0.5 mg sirolimus, as a white, triangular-shaped tablet containing 1 mg sirolimus,
and as a yellow-to-beige triangular-shaped tablet containing 2 mg sirolimus.
The inactive ingredients in Rapamune Oral Solution are Phosal 50 PG® (phosphatidylcholine, propylene glycol, mono- and di-glycerides, ethanol, soy fatty acids, and ascorbyl palmitate) and polysorbate 80. Rapamune Oral Solution contains 1.5% - 2.5% ethanol.
The inactive ingredients in Rapamune Tablets include sucrose, lactose, polyethylene
glycol 8000, calcium sulfate, microcrystalline cellulose, pharmaceutical glaze,
talc, titanium dioxide, magnesium stearate, povidone, poloxamer 188, polyethylene
glycol 20,000, glyceryl monooleate, carnauba wax, dl-alpha tocopherol,
and other ingredients. The 0.5 mg and 2 mg dosage strengths also contain yellow
iron (ferric) oxide and brown iron (ferric) oxide.
Last reviewed on RxList: 5/17/2010




Rapamune Drug Description
RAPAMUNE
(sirolimus) Oral Solution and Tablets

BOX WARNING: IMMUNOSUPPRESSION, USE IS NOT RECOMMENDED IN LIVER OR LUNG
TRANSPLANT PATIENTS

Increased susceptibility to infection and the possible development of
lymphoma and other malignancies may result from immunosuppression

Increased susceptibility to infection and the possible development of lymphoma
may result from immunosuppression. Only physicians experienced in immunosuppressive
therapy and management of renal transplant patients should use Rapamune®.
Patients receiving the drug should be managed in facilities equipped and staffed
with adequate laboratory and supportive medical resources. The physician responsible
for maintenance therapy should have complete information requisite for the follow-up
of the patient [see WARNINGS AND PRECAUTIONS]

The safety and efficacy of Rapamune (sirolimus) as immunosuppressive
therapy have not been established in liver or lung transplant patients, and
therefore, such use is not recommended [see WARNINGS AND PRECAUTIONS].
Liver Transplantation - Excess Mortality, Graft Loss, and Hepatic Artery
Thrombosis (HAT)

The use of Rapamune in combination with tacrolimus was associated with excess
mortality and graft loss in a study in de novo liver transplant patients.
Many of these patients had evidence of infection at or near the time of death.
In this and another study in de novo liver transplant patients, the
use of Rapamune in combination with cyclosporine or tacrolimus was associated
with an increase in HAT; most cases of HAT occurred within 30 days post-transplantation
and most led to graft loss or death [see WARNINGS AND PRECAUTIONS].

Lung Transplantation - Bronchial Anastomotic Dehiscence

Cases of bronchial anastomotic dehiscence, most fatal, have been reported
in de novo lung transplant patients when Rapamune has been used as part
of an immunosuppressive regimen [see WARNINGS AND PRECAUTIONS].

DRUG DESCRIPTION



What are the possible side effects of sirolimus (Rapamune)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

fast heart rate;
pain when you breathe, feeling short of breath;
chest pain, feeling weak or tired;
coughing up blood or mucus;
feeling like you might pass out;
pale skin, easy bruising or bleeding,...
Read All Potential Side Effects for Rapamune »




Rapamune (sirolimus) is an immunosuppressive agent. Sirolimus is a macrocyclic
lactone produced by Streptomyces hygroscopicus. The chemical name of
sirolimus (also known as rapamycin) is (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,
34a-hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]
oxaazacyclohentriacontine-1,5,11,28,29 (4H,6H,31H)-pentone.
Its molecular formula is C51H79NO13 and its
molecular weight is 914.2. The structural formula of sirolimus is illustrated
as follows.








Sirolimus is a white to off-white powder and is insoluble in water, but freely soluble in benzyl alcohol, chloroform, acetone, and acetonitrile.
Rapamune is available for administration as an oral solution containing 1 mg/mL
sirolimus. Rapamune is also available as a tan, triangular-shaped tablet containing
0.5 mg sirolimus, as a white, triangular-shaped tablet containing 1 mg sirolimus,
and as a yellow-to-beige triangular-shaped tablet containing 2 mg sirolimus.
The inactive ingredients in Rapamune Oral Solution are Phosal 50 PG® (phosphatidylcholine, propylene glycol, mono- and di-glycerides, ethanol, soy fatty acids, and ascorbyl palmitate) and polysorbate 80. Rapamune Oral Solution contains 1.5% - 2.5% ethanol.
The inactive ingredients in Rapamune Tablets include sucrose, lactose, polyethylene
glycol 8000, calcium sulfate, microcrystalline cellulose, pharmaceutical glaze,
talc, titanium dioxide, magnesium stearate, povidone, poloxamer 188, polyethylene
glycol 20,000, glyceryl monooleate, carnauba wax, dl-alpha tocopherol,
and other ingredients. The 0.5 mg and 2 mg dosage strengths also contain yellow
iron (ferric) oxide and brown iron (ferric) oxide.
Last reviewed on RxList: 5/17/2010




Rapamune Drug Description
RAPAMUNE
(sirolimus) Oral Solution and Tablets

BOX WARNING: IMMUNOSUPPRESSION, USE IS NOT RECOMMENDED IN LIVER OR LUNG
TRANSPLANT PATIENTS

Increased susceptibility to infection and the possible development of
lymphoma and other malignancies may result from immunosuppression

Increased susceptibility to infection and the possible development of lymphoma
may result from immunosuppression. Only physicians experienced in immunosuppressive
therapy and management of renal transplant patients should use Rapamune®.
Patients receiving the drug should be managed in facilities equipped and staffed
with adequate laboratory and supportive medical resources. The physician responsible
for maintenance therapy should have complete information requisite for the follow-up
of the patient [see WARNINGS AND PRECAUTIONS]

The safety and efficacy of Rapamune (sirolimus) as immunosuppressive
therapy have not been established in liver or lung transplant patients, and
therefore, such use is not recommended [see WARNINGS AND PRECAUTIONS].
Liver Transplantation - Excess Mortality, Graft Loss, and Hepatic Artery
Thrombosis (HAT)

The use of Rapamune in combination with tacrolimus was associated with excess
mortality and graft loss in a study in de novo liver transplant patients.
Many of these patients had evidence of infection at or near the time of death.
In this and another study in de novo liver transplant patients, the
use of Rapamune in combination with cyclosporine or tacrolimus was associated
with an increase in HAT; most cases of HAT occurred within 30 days post-transplantation
and most led to graft loss or death [see WARNINGS AND PRECAUTIONS].

Lung Transplantation - Bronchial Anastomotic Dehiscence

Cases of bronchial anastomotic dehiscence, most fatal, have been reported
in de novo lung transplant patients when Rapamune has been used as part
of an immunosuppressive regimen [see WARNINGS AND PRECAUTIONS].

DRUG DESCRIPTION



What are the possible side effects of sirolimus (Rapamune)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have any of these serious side effects:

fast heart rate;
pain when you breathe, feeling short of breath;
chest pain, feeling weak or tired;
coughing up blood or mucus;
feeling like you might pass out;
pale skin, easy bruising or bleeding,...
Read All Potential Side Effects for Rapamune »




Rapamune (sirolimus) is an immunosuppressive agent. Sirolimus is a macrocyclic
lactone produced by Streptomyces hygroscopicus. The chemical name of
sirolimus (also known as rapamycin) is (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,
34a-hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]
oxaazacyclohentriacontine-1,5,11,28,29 (4H,6H,31H)-pentone.
Its molecular formula is C51H79NO13 and its
molecular weight is 914.2. The structural formula of sirolimus is illustrated
as follows.








Sirolimus is a white to off-white powder and is insoluble in water, but freely soluble in benzyl alcohol, chloroform, acetone, and acetonitrile.
Rapamune is available for administration as an oral solution containing 1 mg/mL
sirolimus. Rapamune is also available as a tan, triangular-shaped tablet containing
0.5 mg sirolimus, as a white, triangular-shaped tablet containing 1 mg sirolimus,
and as a yellow-to-beige triangular-shaped tablet containing 2 mg sirolimus.
The inactive ingredients in Rapamune Oral Solution are Phosal 50 PG® (phosphatidylcholine, propylene glycol, mono- and di-glycerides, ethanol, soy fatty acids, and ascorbyl palmitate) and polysorbate 80. Rapamune Oral Solution contains 1.5% - 2.5% ethanol.
The inactive ingredients in Rapamune Tablets include sucrose, lactose, polyethylene
glycol 8000, calcium sulfate, microcrystalline cellulose, pharmaceutical glaze,
talc, titanium dioxide, magnesium stearate, povidone, poloxamer 188, polyethylene
glycol 20,000, glyceryl monooleate, carnauba wax, dl-alpha tocopherol,
and other ingredients. The 0.5 mg and 2 mg dosage strengths also contain yellow
iron (ferric) oxide and brown iron (ferric) oxide.
Last reviewed on RxList: 5/17/2010





Other reviews about Rapamune on wordpress

A Swell(ing) Journey Part IX: Vanderbilt? Hello? Are You There?
  by Matt
For whatever reason, the fine kidney doctor people at Vanderbilt have never called me or my local doctor back with an appointment time. I tried calling again […]


A Swell(ing) Journey Part XI: The Frustration Chronicles
  by Matt
Eight months.  I've been lugging around an extra 30 to 35 pounds of seemingly unexplainable fluid in the lower half of my body for eight months.  It's kind […]


Multi-Cancer Drug Candidate Being Tested
  by mindthrall
Researchers at the University of California, San Francisco are beginning to test a new category of rapamycins, drugs that block the signal to protein clusters in cancer cells […]


FDA MedWatch - Sirolimus (marketed as Rapamune)
  by irbtipoftheweek
FDA notified healthcare professionals of clinical trial data that suggest increased mortality in stable liver transplant patients after conversion from a calcineurin inhibitor (CNI)-based immunosuppressive regimen to sirolimus […]


Clinical Trial Data that Suggest Increased Mortality in Stable Liver Transplant Patients Receiving Sirolimus [Rapamune]
  by thassodotcom
June 11, 2009 - From a today’s  MedWatch Safety Alert we learn that the American Food and Drug Administration (FDA) notified healthcare professionals of clinical trial data that […]


The Anti-Aging Pill
  by gabatronic
Recent news of a pre-clinical trial that unexpectedly showed anti-rejection drug Rapamycin extend the lifespan of mice has set the world abuzz. The article below goes as far as […]


It sounds like the stuff of science fiction, or at …
  by whatchamacaulay
It sounds like the stuff of science fiction, or at least, something you might find on in a sci-fi channel documentary, possibly narrated by Jonathan Frakes...Perhaps the media […]


FDA MedWatch - Rapamune (sirolimus): Drug Monitoring Recommendations
  by irbtipoftheweek
Wyeth notified healthcare professionals of changes to the Rapamune Prescribing Information regarding changes in the performance of an immunoassay used for therapeutic drug monitoring (TDM) of sirolimus. The […]


Pharma Giant's Subsidiary Accused Of Targeting 'High-Risk' Black Patients For Unapproved Use Of Drug
  by kstreet607
This is the sort of thing that makes you want to shove that "free market" "self-regulation" rhetoric right down the throats of every teabagger, Rand and Ron Paul, […]


Impactiviti Daily 052610 Top Pharma News
  by Steve Woodruff
***** TODAY’S NEWS: Very big news for Vertex - 75% of hepatitis C patients never treated before achieved a viral cure after receiving a 12-week course of the company's […]



Other reviews about Rapamune on web:

Learn about the prescription medication Rapamune (Sirolimus), drug uses, dosage, side effects, drug interactions, warnings, and patient labeling. Rapamune (Sirolimus) Drug Information: Uses, Side Effects, Drug ...


It is marketed under the trade name Rapamune by Wyeth. Sirolimus was originally developed as an antifungal agent. However, this was abandoned when it was discovered that it had potent ... Sirolimus - Wikipedia, the free encyclopedia


Accurate, FDA approved Rapamune information for healthcare professionals and patients - brought to you by Drugs.com. Rapamune Official FDA information, side effects and uses.


All about Rapamune Tablets. View complete and up to date Rapamune information - part of the Drugs.com trusted medication database. Rapamune Tablets Facts and Comparisons at Drugs.com


To report an adverse event or to speak to a member of Pfizer Medical Information, please call 1.800.438.1985 Health Care Professionals Log In


Users share their experience with Rapamune and comment on drug side effects, effectiveness, and treatment knowledge Rapamune Drug and Medication User Reviews on RxList


Rapamune is an immunosuppressant used to prevent organ rejection after a kidney transplant. Side effects and interactions are available at drugstore.com; plus get home delivery ... Rapamune - drugstore.com. Low prices, side effects, interactions.


Consumer information about the medication SIROLIMUS TABLETS - ORAL (Rapamune), includes side effects, drug interactions, recommended dosages, and storage information. Read more ... SIROLIMUS TABLETS - ORAL (Rapamune) side effects, medical uses ...


Learn more about the potentially deadly side effects of Rapamune and determine if you need a Rapamune lawyer. Rapamune Side Effects - Rapamune Lawsuits


Buy Rapamune (Sirolimus) from our Canadian Online Pharmacy by calling 1-877-888-3562. Fully licensed, fast delivery, free doctor consultation provided. Buy Rapamune (Sirolimus) Online Now





Featured Reviews

Reviews Olanzapine Extended Release Injectable Suspension

Zyprexa Relprevv Drug Description ZYPREXA RELPREVV (olanzapine) For Extended Release Injectable Suspension WARNING: POST-INJECTION DELIRIUM/SEDATION SYNDROME AND INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Post-I...
Read More  |  Review This
Reviews Beractant

Survanta Drug Description SURVANTA® (beractant) Intratracheal Suspension Sterile Suspension. For Intratracheal Administration Only DRUG DESCRIPTION What are the possible side effects of beractant (Survanta Intratracheal)? Get...
Read More  |  Review This
Reviews Methylphenidate Transdermal

Daytrana Drug Description Daytrana™ (day-TRON-ah) (methylphenidate) Transdermal System DRUG DESCRIPTION What are the possible side effects of methylphenidate transdermal (Daytrana)? Get emergency medical help if you have...
Read More  |  Review This
Reviews Zonisamide

Zonegran Drug Description ZONEGRAN® (zonisamide) Capsules DRUG DESCRIPTION What are the possible side effects of zonisamide (Zonegran)? Get emergency medical help if you have any of these signs of an allergic reaction:...
Read More  |  Review This
Reviews Hydroxyurea Capsules

Droxia Drug Description DROXIA® (hydroxyurea) Capsules, USP WARNING Treatment of patients with DROXIA may be complicated by severe, sometimes life-threatening, adverse effects. DROXIA should be administered under the supervision...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....